Introduction
Biobanking is recognised as a critical area requiring development if progress is to be made in identifying clinically useful markers of disease and disease progression, discovering new drug targets and understanding the mechanisms of disease in cancer.
Researchers continue to report that they are unable to obtain sufficient high quality, well annotated samples of diseased and control tissue, blood and other biological materials 1 , 2 . At the same time, funders of research, and especially funders of biobanks, are looking to obtain best value from their investments in sample and data collection. There is a need to increase the availability to researchers of large numbers of high quality, well annotated samples of diseased and control tissue, blood and other biological materials and in this way accelerate cancer research.
Researchers report two major problems; the ability to get access to sufficient numbers of samples and the fact that the available samples are not always suitable for their research. The Cancer Genome Atlas (TCGA) group in the US, for example, reported at a meeting of the International Cancer Genomics Consortium that biobanks typically overestimated the quality of the cancer tissue samples they hold 3 .
Research by the European Commission's Joint Research Centre and Institute for
Prospective Technological Studies 4 recognised the need for improved collaboration and networking amongst biobanks. Currently, networks of biobanks, such as the Confederation of Cancer Biobanks in the UK, CNIO Tumour Bank Network in Spain, the Danubian Biobank Consortium, Canadian Tumour Repository Network and the Australasian Biospecimen Network, are working to develop harmonised methods and quality assured procedures to address these issues. The ultimate aim of these networks is to increase the numbers of high quality, well annotated samples that are available to researchers and so accelerate cancer research.
The need for quality assurance is recognised as an essential part of any scientific endeavour 5 , 6 and it is especially important when different organisations work together 7 . If donors, researchers, funders and the biobanks themselves are to be assured that samples and data are of high quality, "inter-operable", made available and used in research there is a need to define sample and data quality, define best practice for biobanks and set up a scheme to confirm that biobanks are following best practice guidelines and achieving high quality.
This paper will discuss the components of a quality assurance system in a biobank, the availability and usefulness of currently available written standards and guidelines and will give some examples of work in this field. Whilst many of the examples used come from cancer biobanking, the principles of quality assurance are applicable to all biobanks storing human tissue or data for research. The paper will give an overview of current thinking on the need for and use of quality assurance in biobanking of human tissue and data.
What is quality assurance?
The simplest definition of quality is "fit for purpose". The purpose of a biobank is to collect, store and distribute high quality samples and data and it may, in addition, process and test the samples. The way in which the biobank performs these tasks needs to be controlled, so that all of the operations of the biobank, including the ways in which the biobank is managed and in which legal and ethical requirements are met, are "fit for purpose".
Organisations control the quality of their activities by implementing a quality management system (QMS). The QMS defines the organisation's quality policy and objectives and ensures that these are achieved through quality assurance (QA) and quality control (QC). QA focuses on the processes through which the product is obtained whereas QC focuses on the product.
Most scientists are familiar with QC, which is "that part of quality assurance that focuses on fulfilling quality requirements" and perform QC as a routine part of their day-to-day activities. QC consists of specific tests defined by the QA or QMS programme to be performed to monitor procurement, processing, preservation and storage, specimen quality and test accuracy. These tests may include but are not limited to: performance evaluations, testing and controls used to determine the accuracy and reliability of the biobank's equipment and operational procedures as well as monitoring of the supplies, reagents, equipment and facilities. participation in proficiency testing schemes and handling of samples and data. As well as having a management system that ensures that the biobank's core processes are "fit for purpose", a biobank must ensure that the samples and data it provides are "fit for purpose" (figure 2).
Quality standards
There is no international standard for technical quality in a biobank, so the Marble those requirements should be met, whereas best practice guidelines give detail on the best ways to achieve such requirements. Best practice guidelines are not compulsory for organisations seeking certification or accreditation if the organisation can justify why they have taken an alternative approach.
None of the guidelines/best practice publications examined by the MAWG was found to be sufficient as an international standard for biobanking so the MAWG compiled i Certification is the procedure by which a third party gives written assurance that a product, process or service conforms to specific requirements. Accreditation is the procedure by which an authoritative body gives formal recognition that a body or person is competent to carry out specific tasks.
ii ISO is the Geneva-based International Organisation for Standardisation. This organisation produces and publishes written standards according to the perceived needs of the international community.
elements from them into the format of an ISO standard specific for biobanks 15 . The document produced contains the requirements for an international standard for biobanking. However, a biobanking standard has not been adopted as a "work item"
by an ISO Technical Committee yet.
The only existing national biobank-specific standard is the French standard, NF S 96- Harmonisation is a process through which procedures and practices are aligned so that they are compatible with one another. This would allow researchers to have knowledge of the differences between samples and take these into account during their research. Standardisation is the process of defining and agreeing upon technical standards, so that samples and data obtained from one biobank are equivalent to those from other biobanks using the standardised methods. Both rely upon biobanks having a common aim and willingness to work together and adapt pre-existing practices.
The definition of a high quality specimen or dataset can be a problem for a biobank.
A researcher working on a specific project, using specific sample types and experimental techniques, can determine which factors will affect his work and ensure that samples and data are collected appropriately to suit his needs. A biobank, in control, and select procedures that provide a balance between the predicted needs of any potential researchers and the available resources within the biobank. There is little scientific evidence supporting one protocol over another thus it is difficult to find justification for the methods chosen and equally difficult to persuade a biobank to change so that it is in line with others.
There is a need for biospecimen research to define evidence-based best practices. research focus. To achieve inter-operable samples and data, practices must, as a minimum, be standardized inside each biobank and harmonised between biobanks. In the meantime, the best that can be done is to validate procedures and keep meticulous records so that any differences between samples can be attributed to the sample itself rather than the way in which it was collected, processed and stored.
At present, many researchers validate the samples they receive from biobanks because they are not able to rely upon the suitability of samples that they have not collected
European Union (EU) member and associated states. See: www.bbmri.eu. iv SPIDIA is a 4-year project, funded by the European Union FP7 which aims to tackle the standardisation and improvement of pre-analytical procedures for in-vitro diagnostics. The proposed research and standardisation activities cover all steps from creation of evidence-based guidelines to creation of tools for the pre-analytical phase to testing and optimisation of these tools through the development of novel assays and biomarkers.
themselves. The purpose of harmonisation and standardisation is to ensure that samples are collected, transported, processed, tested and stored in ways which gives consistently high quality samples and consistently accurate data. This makes the samples and data acceptable to researchers without further testing.
Harmonisation with respect to sample variability
The differences between samples are multi-factorial. Pre-analytical factors affecting the samples occur in-vivo, due to differences between the donors, and after the samples have been removed from the donors, during transport, stabilisation, processing and storage. Examples of pre-analytical variables are shown in figure 3 .
Pre-analytical factors are often outside the control of the biobank. To allow such samples to be used by researchers it is necessary to keep meticulous records and make them available to the researcher. A system for annotating samples with data about pre-analytical factors has been developed by the ISBER Working Group on Biospecimen Science and published as a standard pre-analytical coding for biospecimens (SPREC) 18 . The criteria used to annotate solid tissue samples are shown in figure 4 . This system allows samples to be annotated by a code that describes how they have been obtained and processed, allowing pre-analytical factors to be compared by the researcher. The application of a pre-analytical sample code can not only facilitate a more effective inter-and intra-laboratory specimen utilization by scientists from different biobanks supplying samples for common research and validation exercises, but also allow more effective reporting of research results.
Validation

Validation of biobank's methods, samples and data
Validation can be defined as "establishing documented evidence which provides a high degree of assurance that a specific process will consistently produce a product meeting its pre-determined specification and quality attributes" 19 . Validation of methods, samples and data will enable biobanks, funders and researchers to have confidence in sample quality and so give added credence and reproducibility to the results of research.
Validation can be applied to the "raw" biological material or data, the processing 
Indirect validation of biobank's impact
Whilst this section has concentrated on the quality of samples and data, this is only one aspect of the quality issues in biobanking. The funders of biobanks seek to maximise the return on their investment. Ensuring the quality of the sample and its suitability for use by the researcher is one way that this investment can be maximised, but the funder is interested, also, in ensuring that samples reach the researcher, and so has an interest in the access policies and scientific review procedures that are used when biobanks grant access to samples and data to researchers. From the funders' perspective, numbers of samples used in research and numbers of publications from those samples are also markers of the quality of a biobank. Best practice guidelines are broad based and cover every aspect of running a biobank, considering, for example, legal and ethical issues, sustainability of funding, appropriate levels of anonymisation and methods of determining who has access to samples and data.
These are often the areas where best practices devised in one country may not be applicable elsewhere, since legal and ethical requirements differ between countries, but their control is essential to give confidence to donors, funders and researchers.
Benchmarking of biobanks
Once standards and best practices are defined, it is possible to benchmark biobanks.
In 1999, the OECD suggested that national governments "should support the development of an accreditation system for biobanks based upon scientifically acceptable objective international criteria for quality, expertise and financial stability". This is one way in which biobanks can be benchmarked but there are several options for benchmarking of biobanks, namely self-assessment, peer review or through a formal certification or accreditation procedure.
Self assessment is the simplest and least expensive route. A series of questions can be drawn up based on the required standards and the biobank can rate itself against the questionnaire. ISBER members, for example, have access to a web-based selfassessment tool designed to allow biobanks to assess their compliance with the ISBER best practice guidelines. The main drawback to self assessment is the lack of consistency and transparency in assessments.
Peer review consists of inspection and assessment of compliance with the required standards by experts in the field, such as staff from another biobank or associated organisation. This system is more expensive, requiring staff to be released from their normal work to visit the biobank that is seeking assessment. Its advantage over self assessment is that the assessors can be trained so that assessments are consistent and the relative independence of the assessors gives greater assurance of the validity of the results of the assessment. The assessors, however, are not truly independent since they assess one another's banks; there is a natural "professional courtesy" between such assessors that is to the detriment of the perception of independence since the person whose bank you are assessing today may come to assess your bank next time.
In addition, there are problems with ensuring confidentiality and protecting intellectual property if the assessors are your "competitors". This is handled in most instances by requiring assessors to sign confidentiality agreements but some commercial organisations are not willing to permit peers from competitor organisations on site. Great care is needed when using competitors as assessors.
Certification and accreditation are widely recognised as the "gold standard" ways to assess organisations. The terms certification and accreditation tend to be used interchangeably by "lay" people, however they have different meanings.
Certification is the proof of consistency in the procedures followed. Accreditation is the proof of the competence, the impartiality and the independence of a certification body or laboratory in view of existing norms. Thus an organisation can be certified as 
